Analytical Data
-
Gene name
ASPN
- Application
-
Alternative Names
ASPN;PLAP1;SLRR1C;Asporin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BXN1
-
Expression Region
33-380aa
-
AA Sequence
DMEDTDDDDDDDDDDDDDDEDNSLFPTREPRSHFFPFDLFPMCPFGCQCYSRVVHCSDLGLTSVPTNIPFDTRMLDLQNNKIKEIKENDFKGLTSLYGLILNNNKLTKIHPKAFLTTKKLRRLYLSHNQLSEIPLNLPKSLAELRIHENKVKKIQKDTFKGMNALHVLEMSANPLDNNGIEPGAFEGVTVFHIRIAEAKLTSVPKGLPPTLLELHLDYNKISTVELEDFKRYKELQRLGLGNNKITDIENGSLANIPRVREIHLENNKLKKIPSGLPELKYLQIIFLHSNSIARVGVNDFCPTVPKMKKSLYSAISLFNNPVKYWEMQPATFRCVLSRMSVQLGNFGM
-
Molecular Weight
55.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ASPN, or asporin, is a member of the leucine-rich repeat (LRR) family of proteins and is primarily involved in the regulation of extracellular matrix (ECM) components, particularly in relation to cartilage and bone. Its expression is notably increased in osteoarthritic tissues, suggesting a significant role in joint diseases. Research into ASPN has gained momentum due to its implications in various physiological and pathological processes, including inflammation, tissue repair, and modulating the osteogenic differentiation of mesenchymal stem cells. Moreover, genetic studies have linked ASPN polymorphisms to susceptibility to osteoarthritis and other musculoskeletal disorders, highlighting its potential as a biomarker for disease prediction and progression. Investigating the recombinant form of ASPN provides an insightful avenue to understand its molecular functions and interactions within the ECM. This research not only aims to elucidate the mechanistic pathways involved in ASPN's role in cartilage homeostasis but also paves the way for developing novel therapeutic strategies to target ASPN in joint diseases. Ultimately, understanding the structure-function relationship of recombinant ASPN could lead to breakthrough advancements in regenerative medicine and tissue engineering applications, emphasizing its significance in combatting cartilage degeneration and enhancing joint health.











